The rhizomes and roots of Valeriana fauriei were extracted with 80% aqueous ethanol. This extract was found to exhibit potent inhibitory effects on fat accumulation in 3T3-L1 murine adipocytes. After several steps of chromatographic purification, we succeeded in identifying monovalerianester A as an inhibitor of fat accumulation. Thus, monovalerianester A and the crude extract of the rhizomes and roots of V. fauriei may have therapeutic potential for the treatment of obesity.
Lifestyle-related diseases such as cancer, cardiovascular disease, hypertension, hyperlipidemia, and diabetes are rapidly growing epidemics in developed countries. Obesity is a contributing factor of these diseases [1] . In Japan, the Ministry of Health, Labor and Welfare report that 30% of men and 20% of women are overweight and the number of obese men has increased. Although many antiobesity initiatives such as aerobic exercise have been proposed, we have focused on finding inhibitors of fat accumulation because they could be applied to the development of anti-obesity drugs.
In our previous study, we screened various sources for inhibitors of fat accumulation. We found that a mushroom, Coriolus versicolor, and a plant, Valeriana fauriei, exhibited potent inhibition of fat accumulation in 3T3-L1 murine adipocytes. A highly N-methylated cyclic heptapeptide, (-)-ternatin, was successfully isolated from C. versicolor as a novel inhibitor of fat accumulation [2] [3] [4] . V. fauriei, a Chinese herbal medicine, is used to treat hysteroepilepsy and cardiac palpitation. The clinical effects are mediated by terpenoid glycosides such as kessoglycol diacetate and kessoglycol -monoacetate [5, 6] . A novel iridoid glycoside and a sesquiterpenoid isolated from V. fauriei showed NGF-potentiating activity [7] . We previously isolated 9-hydroxy-10E,12Zoctadecadienoic acid (9-HODE) from V. fauriei as an inhibitor of fat accumulation [8] . In addition, other active fractions were found in extracts from V. fauriei. Here we report the isolation and identification of an inhibitor of fat accumulation other than 9-HODE from V. fauriei. To isolate fat accumulation inhibitors, we applied an assay system using 3T3-L1 murine adipocytes, as described previously [2] . To determine the amount of triglycerides in 3T3-L1 cells, LabAssay TM Triglyceride (Wako Pure Chemical Industries, Ltd., Japan) was used. At the same time, Cell Counting Kit-8 (Dojindo Laboratories, Inc., Japan) was used to determine cell viability. To calculate both fat accumulation (FA) and cell viability (CV) rates, the absorbance values of the samples were divided by the value of the control, which was treated only with vehicle.
The rhizomes and roots of V. fauriei (2 kg), purchased from Tochimoto Tenkaido Co., Ltd. (Japan), were extracted with 80% aqueous ethanol for 2 weeks. The concentrated extract (125 g) was partitioned with ethyl acetate and water, and the ethyl acetate layer was then partitioned with 90% aqueous methanol and hexane. Since the 90% aqueous methanol layer showed inhibitory effects on fat accumulation (FA rate, 66%; CV rate, 93%; conc., 100 g/mL), it was separated by ODS column chromatography with stepwise elution by 70% aqueous MeOH to MeOH. The 70% aqueous MeOH fraction (FA rate, 69%; CV rate, 112%; conc., 50 g/mL) was then subjected to fractionation using silica-gel column chromatography with stepwise elution by CHCl 3 /MeOH (100:1, 20:1, 9:1, 2:1, 0:1). The 9:1 CHCl 3 /MeOH fraction (FA rate, 9%; CV rate, 33%; conc., 50 g/mL) was chromatographed on silica-gel with stepwise elution by n-hexane/AcOEt (1:1, 1:9, 1:19, 0:1) and MeOH. The 1:19 n-hexane/AcOEt fraction (FA rate, 8%; CV rate, 42%; conc., 25 g /mL) and the AcOEt fraction (FA rate, 16%; CV rate, 54%; conc., 25 g/mL) were combined and applied to a silicagel column for chromatography with stepwise elution by CHCl 3 /MeOH (9:1, 2:1, 0:1). The 9:1 CHCl 3 /MeOH fraction (FA rate, 11%; CV rate, 53%; conc., 12.5 g/mL) was finally purified by preparative reversed phase HPLC (50% aqueous MeOH; Cosmosil 5C 18 -AR-II (Nacalai Tesque Inc., Japan), 10×250 mm; UV, 220 nm) to yield 0.7 mg of an active compound.
The active compound was analyzed by 1 H and 13 C NMR (300 MHz, CDCl 3 ) and electrospray ionization mass spectrometry (ESI-MS) to determine the structure. The spectral data are shown in the experimental section. Based on the spectral data, the active compound was identified as a known iridoid, monovalerianester A (1, Figure 1A) . Assignment of the 1 H and 13 C NMR peaks of the active compound was in good agreement with those of monovalerianester A, which have been previously reported [9] . The isolated compound was demonstrated to inhibit fat accumulation in 3T3-L1 murine adipocytes in a dose-dependent manner ( Figure 1B) . FA rate of 50% (EC 50 value) and CV rate of 50% (IC 50 value) were determined to be 3.5 g/mL (11.1 M) and 6.0 g/mL (19.1 M), respectively. The compound showed potent activity compared with the control compound, (-)-noradrenaline (EC 50 =260 M) [10] . Monovalerianester A was isolated from Valeriana officinalis, a species related to V. fauriei [9] . It is the aglycone of kanokoside A (2, Fig. 1 ), which had been identified from the same plant [11] . No studies have evaluated their biological activities in mammalian cells to assess therapeutic potential. In this study, monovalerianester A was found to inhibit fat accumulation in 3T3-L1 murine adipocytes. This finding generated the possibility that its glycoside, kanokoside A, also possesses such function, and its biological activity may contribute to the anti-obesity effect. In our previous study, 9hydroxy-10E,12Z-octadecadienoic acid (9-HODE) was also isolated from the extract of V. fauriei using the same bioassay system [8] .
Meanwhile, the roots and bulbs of V. fauriei have long been used as a traditional herbal medicine, and thus its extract must be safe.
Since monovalerianester A, as well as 9-HODE, were shown to suppress fat accumulation selectively, they and the crude extract of the rhizomes and roots of V. fauriei may have therapeutic potential for the treatment of obesity.
In conclusion, we searched for a new plant component that could inhibit fat accumulation in 3T3-L1 murine adipocytes, and isolated monovalerianester A from the rhizomes and roots of V. fauriei. Monovalerianester A was shown to inhibit fat accumulation in a dose-dependent manner. These results suggested that monovalerianester A and the crude extract of the rhizomes and roots of V. fauriei may be useful as anti-obesity agents.
Experimental
General: 1 H and 13 C NMR spectra were recorded with a JEOL JNM AL300 FT NMR spectrometer. HR-ESI mass spectra were recorded on a Waters LTC premier EX spectrometer.
Measurement of fat accumulation and cell viability:
The preadipocyte cell line 3T3-L1, purchased from Human Science Research Resources Bank, Japan Health Sciences Foundation (Osaka, Japan), was cultured in DMEM with 10% FBS in two 96-well plates at 37°C, 5% CO2 for 4-7 days [12] [13] [14] . After the cells reached confluence, the culture buffer was changed to a differentiation buffer (DMEM containing 10% FBS, 1 M dexamethasone, 0.5 mM IBMX, 90 U/mL penicillin, 90 g/mL streptomycin, and 10 g/mL insulin) and the samples were added [15, 16] . After 7 days, the differentiated 3T3-L1 adipocytes in a 96-well plate were treated with 2% Triton-X 100 for 30 min at room temperature followed by sonication for 1 min. Fat accumulation was determined by measuring liberated triglyceride using LabAssay TM Triglyceride (Wako Pure Chemical Industries, Ltd., Japan). To determine the cell viability of differentiated 3T3-L1 adipocytes, another 96-well plate was treated with a Cell Counting Kit-8 Test (Dojindo Laboratories, Inc., Japan), and the absorbance at 450 nm was measured. Values are means ± SD for triplicate samples.
